Clinical Observation of Caleium Dibulyryl Cyclic Adenosine Monophate and Sheng-mai, Astragalus Injection in treatment of Chronic Heart Failure

LI Xin-jun; QI Shu-ying

doi:10.3969/j.issn.1002-3429.2015.06.025

Abstract：Objective To observe the clinical effect of Caleium dibulyryl cyclic adenosine monophate and Sheng-mai injection and Astragalus injection to treat chronic heart failure ( CHF) . Methods 80 patients with CHF were randomly divid-ed into two groups (n=40); control group was given conventional heart failure (cardiac, diuretic) treatment. Study group (n=40), in addition to the conventional therapy, was given the Caleium dibulyryl cyclic adenosine monophate Sheng-mai in-jection, and Astragalus injection. The course of treatment of the two groups was two weeks. The efficacy of treatment was com-pared. Results The heart function of the two groups after treatment was improved. The total efficiency of the study group was 95. 0% while the control group was 80. 0%(P<0. 05). The result of 6min walk test:The total efficiency of the study group was 87. 5%, while the control group was 75. 0%. The difference was statistically significant(P<0. 05). The comparison of plasma NT-pro BNP levels: After 2 weeks of treatment, the NT-pro BNP levels of the two groups were decreased, and the study group was more significantly than control group. The difference was statistically significant(P<0. 05). After 2 weeks of treatment, the LVEPO of both groups was reduced. The LVEF and CO were improved(P<0. 05). The study group was better than the control group and the difference was statistically significant(P<0. 01). The two groups were not found with signifi-cant adverse reactions. Conclusion Caleium dibulyryl cyclic adenosine monophate and Sheng-mai injection and Astragalus injection in treatment of chronic heart failure is safe and effective in improving heart function with good prognosis and better quality of life.